Prospective study one-year clinical outcomes of the Calypso coronary stent in patients presenting with acute coronary syndrome
Published 2017-04-25
Keywords
- coronary stent,
- acute coronary syndrome,
- Calypso
How to Cite
Copyright (c) 2017 Vorobev V.L., Semenihin A.A., Grachev N.I., Verin V.V.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
Aim. To evaluate the effectiveness of the stent use Calypso Angiolain Russia with primary percutaneous transluminal coronary angioplasty (PTCA).
Methods. The study prospectively included 150 patients who underwent PTCA in acute coronary syndrome (ACS) for the period from January to December 2015. During the one-year follow-up period were evaluated indicators insolvency target lesion (cardiac death, myocardial infarction in the pool target artery, target lesion revascularization when clinically indicated), major adverse cardiac events (death from any cause, myocardial infarction, repeat revascularization as clinically indicated).
Results. In one year, the incidence of target lesion failure was 6.66% for cardiac death rate of 1.33%, myocardial infarction in the target artery 3.33% and target lesion revascularization at 5.3%. The frequency of cardiac major adverse cardiac events was 12% at mortality 2.66%, myocardial infarction 4% and revascularization when clinically indicated 8.66%.
Conclusion. The use of stents in primary PTCA Calypso is possible, the percentage of cardiovascular complications is comparable with the data of clinical trials.
Received 31 January 2017. Accepted 17 March 2017.
Financing: The study did not have sponsorship.
Conflict of interest: The authors declare no conflict of interest.
References
- Laarman G.J., Suttorp M.J., Dirksen M.T., van Heerebeek L., Kiemeneij F., Slagboom T., van der Wieken L.R., Tijssen J.G., Rensing B.J., Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355(11):1105-13. http://dx.doi.org/10.1056/NEJMoa062598.
- Park K.W., Kang S.H., Velders M.A., Shin D.H., Hahn S., Lim W.H., Yang H.M., Lee H.Y., Van Boven A.J., Hofma S.H., Kang H.J., Koo B.K., Oh B.H., Park Y.B., Kandzari D.E., Kim H.S. Safety and efficacy of everolimus- versus sirolimus-eluting stents: A systematic review and meta-analysis of 11 randomized trials. Am Heart J. 2013. 165(2):241-50. http://dx.doi.org/10.1016/j.ahj.2012.08.007.
- Jin Q-H., Chen Y-D., Tian F., Guo J., Jing J., Sun Z-J. Vessel healings after stenting with different polymers in STEMI patients. J Geriatr Cardiol. 2016;13(4):306-11. http://dx.doi.org/10.11909/j.issn.1671-5411.2016.04.004.
- Colleran R., Kufner S., Harada Y., Giacoppo D., Cassese S., Repp J., Wiebe J., Lohaus R., Lahmann A., Schneider S., Ibrahim T., Laugwitz K.L., Kastrati A., Byrne R.A. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction. Catheterization and Cardiovascular Interventions. 2016;88(1):1-161. http://dx.doi.org/10.1002/ccd.26597.
- Бокерия Л.А., Алекян Б.Г. Рентгенэндоваскулярные диагностика и лечение заболеваний сердца и сосудов Российской Федерации – 2015 год. М.: НЦССХ им. А.Н. Бакулева, 2016. 222 с. [Bokeriya L.A., Alekyan B.G. Roentgenoendovascular Diagnostics and Treatment of Cardiovascular Disease in Russia – 2015. Moscow: NCSSH im. A.N. Bakuleva Publ.; , 222 p. (In Russ.)]
- Прохорихин А.А., Верин В.В., Осиев А.Г., Ганюков В.И., Протопопов А.В., Демин В.В., Абугов С.А., Байструков В.И., Гражданкин И.О., Пономарев Д.Н., Кретов Е.И. Простое слепое проспективное рАндомизированное мультиценТровое исследование эффективности и безопасности сиролимус-доставляющего коРонарного стента «КалИпсО» по сравнению с эверолимус-доставляющим сТентом Xience Prime. Патология кровообращения и кардиохирургия. 2016;20(4):96-101. http://dx.doi.org/10.21688/1681-3472-2016-4-96-101 [Prokhorikhin A.A., Verin V.V., Osiev A.G., Ganyukov V.I., Protopopov A.V., Dyomin V.V., Abugov S.A., Baystrukov V.I., Grazhdankin I.O., Ponomaryov D.N., Kretov E.I. Prospective rAndomized, single-blind, mulTicenter control clinical study of sirolimus-eluting coRonary stent “Calypso” vs everolimus-elutIng cOronary stenT “Xience Prime”: design and rationale for “PATRIOT” trial. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2016;20(4):96-101. (In Russ.). http://dx.doi.org/10.21688/1681-3472-2016-4-96-101]
- Kim H.S., Lee J.H., Lee S.W., Kim Y.H., Park J.H., Choi S.W., Jeong J.O., Seong I.W., Rhee K.S., Ko J.K., Jo S.H., Choi Y.J. Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. Int J Cardiol. 2011;147(2):253-7. http://dx.doi.org/10.1016/j.ijcard.2009.09.466
- Ганюков В.И., Тарасов Р.С., Бохан Н.С., Шилов А.А., Шушпанников П.А., Моисеенков Г.В., Барбараш О.Л. Безопасность применения зотаролимус покрытых стентов в лечении пациентов с острым коронарным синдромом в зависимости от наличия или отсутствия элевации сегмента ST. Сибирский медицинский журнал. 2011;26(2-1):51-5. [Ganyukov V.I., Tarasov R.S., Bokhan N.S., Shilov A.A., Shushpannikov P.A., Moiseenkov G.V., Barbarash O.L. Safety of zotarolimus-eluting stent implantation in acute coronary syndrome patients with or without ST-elevation. Sibirskiy meditsinskiy zhurnal = Siberian Medical Journal. 2011;26(2-1):51-5]
- Bil J., Gil RJ., Kern A., Pawłowski T., Seweryniak P., Śliwiński Z. Novel sirolimus-eluting stent Prolim® with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis. BMC Cardiovascular Disorders. 2015;15:150. http://dx.doi.org/10.1186/s12872-015-0139-5